Pratik Shah Trust Amends ARS Pharma Stake

TL;DR

Pratik Shah Trust updated its ARS Pharma filing on 6/17. Watch for changes.

AI Summary

The Pratik Shah Living Trust, dated June 15, 2011, has amended its Schedule 13D filing for ARS Pharmaceuticals, Inc. on June 17, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or percentage changes are not detailed in this excerpt. The trust is associated with ARS Pharmaceuticals' business address in San Diego, CA.

Why It Matters

Amendments to Schedule 13D filings often signal significant changes in a major shareholder's position, potentially impacting stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Schedule 13D amendments can indicate shifts in significant beneficial ownership, which may lead to price volatility.

Key Numbers

• 20240617 — Filing Date (Date of amendment filing)

Key Players & Entities

• Pratik Shah Living Trust dated June 15, 2011 (company) — Filing entity
• ARS Pharmaceuticals, Inc. (company) — Subject company
• Kathleen Scott (person) — Authorized contact

FAQ

Key Financial Figures

• $0.0001 — 11, 2024, relates to the common stock, $0.0001 par value per share (the Common Stock),

Filing Documents

• d854552dsc13da.htm (SC 13D/A) — 36KB
• 0001193125-24-162824.txt ( ) — 37KB

From the Filing

SC 13D/A 1 d854552dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D U NDER THE S ECURITIES E XCHANGE A CT OF 1934 (Amendment No. 2)* ARS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82835W 108 (CUSIP Number) Kathleen Scott ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, CA 92130 (858) 771-9307 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 13, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 82835W 108 13D 1. Name of Reporting Persons The Pratik Shah Living Trust dated June 15, 2011(1) 2. Check the Appropriate Box if a Member of a Group (see instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (see instructions) PF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization United Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 5,219,124 Shares (2) 8. Shared Voting Power 0 9. Sole Dispositive Power 5,219,124 Shares (2) 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5,219,124 Share s 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) 13. Percent of Class Represented by Amount in Row 11 5.4 % (3) 14. Type of Reporting Person (see instructions) OO (1) Pratik Shah, Ph.D. is the Trustee of the Reporting Person. (2) Includes 394,570 shares of common stock issuable within 60 days of June 13, 2024 upon the exercise of stock options held by Dr. Shah. (3) This percentage is calculated based on 96,895,256 shares of common stock outstanding as of May 6, 2024, as reported on the Issuers Quarterly Report on Form 10-Q filed on May 9, 2024. CUSIP No. 82835W 108 13D Explanatory Note: This Amendment No. 2, which amends the Schedule 13D filed with the Securities and Exchange Commission on November 18, 2022, filed on behalf of The Pratik Shah Living Trust dated June 15, 2011, and amended on June 11, 2024, relates to the common stock, $0.0001 par value per share (the Common Stock), of ARS Pharmaceuticals, Inc., a Delaware corporation (the Issuer). Capitalized terms used but not defined herein have the meanings given to such terms in the Original Schedule 13D. Item4. Purpose of Transaction. Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4: On June 13, 2024, Dr. Shahs spouse transferred (i) 200,000 shares of Common Stock to Dr. Shahs father-in-law, and (ii) 1,132,900 shares of Common Stock to The Guide 2024 Irrevocable Trust of which Dr. Shahs spouse is the settlor. Item5. Interest in Securities of the Issuer. (a)(b) The following information with respect to the ownership of Common Stock of the Issuer by the person filing this Entity Shares Held Directly Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Beneficial Percentage of Class (1) The Pratik Shah Living Trust dated June 15, 2011 5,219,124 5,219,124 0 5,219,124 0 5,219,124 5.4 % (1) This percentage is calculated based on 96,895,256 shares of common stock outstanding as of May 6, 2024, as reported on the Issuers Quarterly Report on Form 10-Q filed on May 9, 2024. (c) Except as set forth herein, the Reporting Person has not effected any transactions in shares of the Issuers Common Stock during the last 60 days. (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Person. (e) Not applicable. CUSIP No. 82835W 108 13D SIGNAT

View Full Filing

View this SC 13D/A filing on SEC EDGAR